Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SALVOVAR

Financiado

A EUROPEAN MULTI-DISCIPLINARY CLINICAL PROJECT MEANT TO IMPROVE THE MANAGEMENT O...

A EUROPEAN MULTI-DISCIPLINARY CLINICAL PROJECT MEANT TO IMPROVE THE MANAGEMENT OF PATIENTS WITH POOR PROGNOSTIC OVARIAN CANCER AFTER NEOADJUVANT CHEMOTHERAPY: RESTORING HOPE, SALVAGING LIVES The standard medical-and-surgical treatment of ovarian carcinoma patients relies on a systemic chemotherapy (carboplatin-paclitaxel), a tumor debulking surgery meant to be complete (no post-operative residual lesion), and a subseq... ver más

30/04/2028

Laboratoire d’Ecol...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

CNRS UMR 5023 No se ha especificado una descripción o un objeto social para esta compañía.

Ver 11 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-24

HORIZON-MISS-2022-CANCER-01-03: Pragmatic clinical trials to optimi... ExpectedOutcome:While cancer research and innovation have generated novel treatment options, cancer...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

Laboratoire d’Ecologie des H...

727.14K€ | Lider

INSTITUT GUSTAVE ROUSSY

113.13K€ | Participante

FUNDACIO PRIVADA PER LA RECE...

474.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2017-85869-R MECANISMOS DE SEÑALIZACION Y CONTROL METABOLICO IMPLICADOS E... 182K€ Cerrado

CNS2023-145629 Herramientas diagnósticas, pronósticas y terapéuticas 400K€ Cerrado

RTC-2015-3821-1 DESARROLLO DE NUEVAS APROXIMACIONES EN EL MANEJO INDIVIDUALI... 724K€ Cerrado

PGC2018-101899-B-I00 RESPUESTA DEL SISTEMA INMUNE INNATO FRENTE A METASTASIS PERI... 321K€ Cerrado

SAF2011-26548 IDENTIFICACION DE NUEVAS MOLECULAS Y MECANISMOS DE INFILTRAC... 133K€ Cerrado

MetaboMARKER A metabolism based prognostic biomarker for prostate cancer 150K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2023-04-24
Fecha Fin: 2028-04-30

Líder del proyecto

CNRS UMR 5023 No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 7M€

Descripción del proyecto The standard medical-and-surgical treatment of ovarian carcinoma patients relies on a systemic chemotherapy (carboplatin-paclitaxel), a tumor debulking surgery meant to be complete (no post-operative residual lesion), and a subsequent maintenance treatment with modern targeted agents. Recent studies identified a patient population (~14,000 patients / year in Europe), whose prognostic is poor (5 year-overall survival (OS) <20%) due to a refractory cancer, characterized by a poor chemosensitivity (assessable online with the numeric CA-125 KELIMTM score <1.0), and by a disease found non-resectable disease after 3-4 cycles of chemotherapy. In these patients, there is a high uncertainty about the best treatment adjustments to apply. SALVOVAR is a European project led by HCL, meant 1) to raise the physician awareness, and propose practical and affordable diagnostic tools for identifying these patients, and 2) to assess the utility (OS benefit), acceptability (quality-of-life; patient perception) and affordability (cost-effectiveness, including country coverage policies) of solutions based on adjustments of their medical-and-surgical treatment. These solutions implementable in routine may improve their prognosis, according to recent literature data. The project will be based on a large pragmatic randomized phase III trial, sponsored by ARCAGY-GINECO group, and activated in 6 countries (ENGOT network; ~100 recruiting centers), with the objective of demonstrating an OS benefit with the chemotherapy densification (weekly carboplatine-paclitaxel dose-dense regimen) compared to the continuation of the standard 3-weekly regimen. Total 685 patients treated with the standard neo-adjuvant chemotherapy will be pre-screened to randomize 240 patients. Dissemination, and communication will be carried-on to ensure the quality of the project, and inform the stakeholders, patients, public, health authorities/ payers of the project outcomes, mean to change the practices. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores